Roche has announced that it is building a second high-tech manufacturing facility in Shanghai to produce the cancer medicine Xeloda and the transplantation medicine CellCept for the Chinese market as of 2006. The production facility is designed fully to international standards, complying with GMP regulations and safety, health and environmental principles. Both Xeloda and CellCept are major medicines in the Roche portfolio. Xeloda is a tumour-activated oral chemotherapeutic agent used to treat breast and colorectal cancer. CellCept, used as a foundation for immuosuppression, helps transplant patients to live a longer and healthier life.
Looking for more projects or tenders? This is just the tip of the iceberg! Subscribe today to our Projects & Tenders newsletter.
